Cancer Detection Rates of Systematic and Targeted Prostate Biopsies after Biparametric MRI
Copyright © 2020 Maudy C. W. Gayet et al..
OBJECTIVE: To compare prostate cancer detection rates (CDRs) and pathology results with targeted prostate biopsy (TB) and systematic prostate biopsy (SB) in biopsy-naive men.
METHODS: An in-patient control study of 82 men undergoing SB and subsequent TB in case of positive prostate MRI between 2015 and 2017 in the Jeroen Bosch Hospital, the Netherlands.
RESULTS: Prostate cancer (PCa) was detected in 54.9% with 70.7% agreement between TB and SB. Significant PCa (Gleason score ≥7) was detected in 24.4%. The CDR with TB and SB was 35.4% and 48.8%, respectively (p=0.052). The CDR of significant prostate cancer with TB and SB was both 20.7%. Clinically significant pathology upgrading occurred in 7.3% by adding TB to SB and 22.0% by adding SB to TB.
CONCLUSIONS: There is no statistically significant difference between CDRs of SB and TB. Both SB and TB miss significant PCas. Moreover, pathology upgrading occurred more often by adding SB to TB than vice versa. This indicates that the omission of SB in this study population might not be justified.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2020 |
|---|---|
| Enthalten in: |
Prostate cancer - 2020(2020) vom: 11., Seite 4626781 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gayet, Maudy C W [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 14.04.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1155/2020/4626781 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308937643 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308937643 | ||
| 003 | DE-627 | ||
| 005 | 20231226201340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1155/2020/4626781 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1029.xml |
| 035 | |a (DE-627)NLM308937643 | ||
| 035 | |a (NLM)32308996 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gayet, Maudy C W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cancer Detection Rates of Systematic and Targeted Prostate Biopsies after Biparametric MRI |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2020 Maudy C. W. Gayet et al. | ||
| 520 | |a OBJECTIVE: To compare prostate cancer detection rates (CDRs) and pathology results with targeted prostate biopsy (TB) and systematic prostate biopsy (SB) in biopsy-naive men | ||
| 520 | |a METHODS: An in-patient control study of 82 men undergoing SB and subsequent TB in case of positive prostate MRI between 2015 and 2017 in the Jeroen Bosch Hospital, the Netherlands | ||
| 520 | |a RESULTS: Prostate cancer (PCa) was detected in 54.9% with 70.7% agreement between TB and SB. Significant PCa (Gleason score ≥7) was detected in 24.4%. The CDR with TB and SB was 35.4% and 48.8%, respectively (p=0.052). The CDR of significant prostate cancer with TB and SB was both 20.7%. Clinically significant pathology upgrading occurred in 7.3% by adding TB to SB and 22.0% by adding SB to TB | ||
| 520 | |a CONCLUSIONS: There is no statistically significant difference between CDRs of SB and TB. Both SB and TB miss significant PCas. Moreover, pathology upgrading occurred more often by adding SB to TB than vice versa. This indicates that the omission of SB in this study population might not be justified | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a van der Aa, Anouk A M A |e verfasserin |4 aut | |
| 700 | 1 | |a Beerlage, Harrie P |e verfasserin |4 aut | |
| 700 | 1 | |a Schrier, Bart Ph |e verfasserin |4 aut | |
| 700 | 1 | |a Gielens, Maaike |e verfasserin |4 aut | |
| 700 | 1 | |a Heesakkers, Roel |e verfasserin |4 aut | |
| 700 | 1 | |a Jager, Gerrit J |e verfasserin |4 aut | |
| 700 | 1 | |a Mulders, Peter F A |e verfasserin |4 aut | |
| 700 | 1 | |a Wijkstra, Hessel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Prostate cancer |d 2012 |g 2020(2020) vom: 11., Seite 4626781 |w (DE-627)NLM217260098 |x 2090-3111 |7 nnns |
| 773 | 1 | 8 | |g volume:2020 |g year:2020 |g day:11 |g pages:4626781 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1155/2020/4626781 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2020 |j 2020 |b 11 |h 4626781 | ||